Nano PharmaSolutions, Inc. has solved these cumbersome physical attributes of ultra-small particulates by proprietary platform technology of generating nanoparticles of drugs under ultra-low pressure and in situ coating of the nanoparticles onto a solid matrix commonly used in formulation, namely mannitol, lactose, or other hydrophilic filler/binder. Furthermore, our technology can generate submicron-size drug particles at very gentle conditions quickly, so degradation of API does not take place. Once nano-sized drug particles are coated onto the porous surface of the carrier get dislodged under regular storage and handling conditions. Hydrophilic carriers we use, such as mannitol or lactose, are commonly used in most solid oral dosage forms; therefore, the nanoparticle drug-coated filler/binder may be incorporated into granules, capsules, and tablets in conventional formulation.

By using ultra-low pressure under high vacuum, Nano PharmaSolution’s technology can transform solid API into vapor phase molecules at low temperature quickly, which is then captured by rapidly moving carrier solid (e.g. mannitol) in uniform thin layers, often a single layer (Figure 2). When the nano-drug-coated carrier powder is mixed with water in vitro or in vivo, these water-soluble carriers (mannitol or lactose) dissolve quickly, leaving nanoparticles of drug suspended in water (Figure 3). Since mannitol, lactose, or other water-soluble excipients that are used in most oral formulations are used as the carrier solid, and the drug-coated carrier can be directly incorporated into oral dosage form, NPS’ physical milling technology does not require any additional excipients than the ones already used in routine formulation; therefore, no additional chemical is required to achieve nanosized drug particles.

In-situ Formation of Nanodrug-coated-Carrier
In-situ Formation of Nanodrug-coated-Carrier
How Drug Nanoparticles are freed in water

Development time is very fast, often as little as a few weeks since NPS’ phase-transition technology has wide applicability to all classes of small molecule APIs. The API requirement for initial evaluation for in vitro dissolution and animal PK study is as little as 10 gram. This technology can be applied to both new drug candidates and generic drug application. Please contact information@nanopharmasolutions.com for your nano formulation discussion.